Avantor, Inc. (AVTR) Securities Class Action Lawsuit Filed [November 5, 2025]

Introduction to Avantor, Inc. (AVTR) Securities Class Action Lawsuit

A federal securities fraud class action has been filed against Avantor, Inc. (NYSE: AVTR) covering trades from March 5, 2024 through October 28, 2025. Investors allege the company and senior executives overstated Avantor's competitive strength and downplayed rising competitive pressures. During this period, executives repeatedly described leadership across key markets and forecast growth, while the complaint contends competition was already eroding volumes and margins. The truth emerged through a series of disclosures in 2025 admitting intensified competition, lost accounts, weaker results, and a large goodwill impairment. As these disclosures landed, Avantor's stock fell sharply on multiple dates, causing significant investor losses.

Avantor, Inc. (AVTR) Securities Lawsuit Case Details

Case Name: Building Trades Pension Fund of Western Pennsylvania v. Avantor, Inc., et al.
Case No.: 2:25-cv-06187
Jurisdiction: U.S. District Court, Eastern District of Pennsylvania
Filed on: October 30, 2025

Avantor, Inc. (AVTR) Company Profile

Avantor is a life science tools company that provides scientific products and services to customers in biotechnology, pharmaceuticals, healthcare, education, government, and other industries. The company reports results in two segments: Laboratory Solutions, which accounts for approximately two-thirds of net sales, and Bioscience Production.

Avantor, Inc. (AVTR) Securities Lawsuit Class Period

March 5, 2024–October 28, 2025, inclusive.

All persons and entities who purchased or otherwise acquired Avantor common stock during the Class Period may be eligible to join the Avantor, Inc. (AVTR) class action lawsuit.

Allegations in the Avantor, Inc. (AVTR) Securities Class Action Lawsuit

According to the complaint, Avantor, along with then-CEO Michael Stubblefield and CFO R. Brent Jones, told investors the company held a strong competitive position and leadership across key markets. Investors allege these statements painted a picture of momentum and share gains that did not align with mounting competitive pressures.  

The narrative begins on March 5, 2024, when Stubblefield told investors at a TD Cowen healthcare conference that Avantor had a "really terrific year" and was "clearly taking share," emphasizing strength in academia and biopharma. On May 30, 2024, at the Sanford C. Bernstein Strategic Decisions Conference, he asserted Avantor would "be the leader" in process ingredients, materials, and single‑use solutions. Then on June 11, 2024, at a Goldman Sachs healthcare conference, he highlighted Avantor's "sophisticated quality and regulatory expertise" and said larger players in end markets were not viewed as competitors.

The message continued through earnings. On July 26, 2024, during the second quarter 2024 call, Stubblefield said the lab business "stacks up well" and that management was "really confident in our value proposition and our competitive position." On October 25, 2024, on the third quarter 2024 call, he described Avantor as "clearly a leader" in Laboratory Solutions with favorable positioning and momentum. On February 7, 2025, Jones told investors the company was entering 2025 "well positioned for growth," projecting 1% to 3% organic revenue growth and double‑digit EPS growth.

The complaint alleges that, behind these assurances, Avantor's competitive positioning was weaker than represented and the company was already experiencing negative effects from increased competition. As the period progressed, management's later disclosures on April 25, 2025, August 1, 2025, and October 29, 2025—events included in the complaint's chronology—described intensified competition, guidance cuts, and lost accounts, which investors allege undercut earlier claims of leadership and growth.

The Truth Emerges

By April 25, 2025, the story shifted. On that date, Avantor reported weak first quarter 2025 results, cut its 2025 guidance, and announced the CEO's resignation, while Jones admitted the company had "felt the impact of increased competitive intensity," including reduced volumes at a handful of customers. Three months later, on August 1, 2025, Avantor reported disappointing second quarter results, reduced guidance to negative to flat organic revenue growth, and warned that the competitive environment would not change materially in 2025. 

Finally, on October 29, 2025, Avantor reported weak third quarter results with -5% organic revenue growth and a $712 million net loss, driven primarily by a $785 million goodwill impairment charge attributed to competitive pressures. Management further disclosed that the company had lost a couple of large accounts and that competition had pressured pricing and margins.

Market Reaction

Avantor's stock declined following each disclosure. On April 25, 2025, Avantor's stock fell $2.57 per share, more than 16.5%, from $15.50 on April 24 to close at $12.93. On August 1, 2025, the stock declined another $2.08 per share, or more than 15%, closing at $11.36 from $13.44 the prior day.

The losses deepened on October 29, 2025, when shares dropped $3.50 per share, or more than 23%, from a $15.08 close on October 28 to $11.58, following the disclosure of third quarter results, the net loss, and the goodwill impairment.

Next Steps

• Submissions for lead plaintiff are due: December 29, 2025
• The Court will issue its order for lead plaintiff and counsel in the weeks after submissions are due.
• The Court will then consider motion for class certification.
• The Court will later consider a Motion to Dismiss.

To learn if you are eligible for recovery under the AVTR securities class action lawsuit, visit the case submission page here.

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.